StreetInsider.com News Articles

Quest Diagnostics (DGX) PT Raised to $236 at Baird

Mon, 13 Jul 2026 07:20:41 -0400

Baird analyst Eric Coldwell raised the price target on Quest Diagnostics (NYSE: DGX) to $236.00 (from $232.00) while maintaining a Neutral rating.

One in Five American Workers Tested Had a Positive Hair Drug Test in 2025, Signaling Persistent Long-Term Substance Use Patterns

Fri, 10 Jul 2026 09:24:00 -0400

Hair test positivity among American workers reached 19.1% in 2025, potentially reflecting recurring or chronic drug use
15.1% of workers screened for drugs using a hair test were positive for marijuana – up 58.9% from five years ago
Overall workforce urine drug positivity remained above 4% for more than a decade
Healthcare workers scored highest for overall drug positivity, at 5.8%; retail trade had the highest marijuana positivity among worker categories, at 7.6%
Fentanyl positivity declines by nearly half in the general U.S. workforce

SECAUCUS, N.J., July 10, 2026 /PRNewswire/ -- Nearly one in five

One in Five American Workers Tested Had a Positive Hair Drug Test in 2025, Signaling Persistent Long-Term Substance Use Patterns

Fri, 10 Jul 2026 09:24:00 -0400

Hair test positivity among American workers reached 19.1% in 2025, potentially reflecting recurring or chronic drug use
15.1% of workers screened for drugs using a hair test were positive for marijuana – up 58.9% from five years ago
Overall workforce urine drug positivity remained above 4% for more than a decade
Healthcare workers scored highest for overall drug positivity, at 5.8%; retail trade had the highest marijuana positivity among worker categories, at 7.6%
Fentanyl positivity declines by nearly half in the general U.S. workforce

SECAUCUS, N.J., July 10, 2026 /PRNewswire/ -- Nearly one in five

One in Five American Workers Tested Had a Positive Hair Drug Test in 2025, Signaling Persistent Long-Term Substance Use Patterns

Fri, 10 Jul 2026 09:24:00 -0400

Hair test positivity among American workers reached 19.1% in 2025, potentially reflecting recurring or chronic drug use
15.1% of workers screened for drugs using a hair test were positive for marijuana – up 58.9% from five years ago
Overall workforce urine drug positivity remained above 4% for more than a decade
Healthcare workers scored highest for overall drug positivity, at 5.8%; retail trade had the highest marijuana positivity among worker categories, at 7.6%
Fentanyl positivity declines by nearly half in the general U.S. workforce

SECAUCUS, N.J., July 10, 2026 /PRNewswire/ -- Nearly one in five

One in Five American Workers Tested Had a Positive Hair Drug Test in 2025, Signaling Persistent Long-Term Substance Use Patterns

Fri, 10 Jul 2026 09:24:00 -0400

Hair test positivity among American workers reached 19.1% in 2025, potentially reflecting recurring or chronic drug use
15.1% of workers screened for drugs using a hair test were positive for marijuana – up 58.9% from five years ago
Overall workforce urine drug positivity remained above 4% for more than a decade
Healthcare workers scored highest for overall drug positivity, at 5.8%; retail trade had the highest marijuana positivity among worker categories, at 7.6%
Fentanyl positivity declines by nearly half in the general U.S. workforce

SECAUCUS, N.J., July 10, 2026 /PRNewswire/ -- Nearly one in five

One in Five American Workers Tested Had a Positive Hair Drug Test in 2025, Signaling Persistent Long-Term Substance Use Patterns

Fri, 10 Jul 2026 09:24:00 -0400

Hair test positivity among American workers reached 19.1% in 2025, potentially reflecting recurring or chronic drug use
15.1% of workers screened for drugs using a hair test were positive for marijuana – up 58.9% from five years ago
Overall workforce urine drug positivity remained above 4% for more than a decade
Healthcare workers scored highest for overall drug positivity, at 5.8%; retail trade had the highest marijuana positivity among worker categories, at 7.6%
Fentanyl positivity declines by nearly half in the general U.S. workforce

SECAUCUS, N.J., July 10, 2026 /PRNewswire/ -- Nearly one in five

One in Five American Workers Tested Had a Positive Hair Drug Test in 2025, Signaling Persistent Long-Term Substance Use Patterns

Fri, 10 Jul 2026 09:24:00 -0400

Hair test positivity among American workers reached 19.1% in 2025, potentially reflecting recurring or chronic drug use
15.1% of workers screened for drugs using a hair test were positive for marijuana – up 58.9% from five years ago
Overall workforce urine drug positivity remained above 4% for more than a decade
Healthcare workers scored highest for overall drug positivity, at 5.8%; retail trade had the highest marijuana positivity among worker categories, at 7.6%
Fentanyl positivity declines by nearly half in the general U.S. workforce

SECAUCUS, N.J., July 10, 2026 /PRNewswire/ -- Nearly one in five

One in Five American Workers Tested Had a Positive Hair Drug Test in 2025, Signaling Persistent Long-Term Substance Use Patterns

Fri, 10 Jul 2026 09:24:00 -0400

Hair test positivity among American workers reached 19.1% in 2025, potentially reflecting recurring or chronic drug use
15.1% of workers screened for drugs using a hair test were positive for marijuana – up 58.9% from five years ago
Overall workforce urine drug positivity remained above 4% for more than a decade
Healthcare workers scored highest for overall drug positivity, at 5.8%; retail trade had the highest marijuana positivity among worker categories, at 7.6%
Fentanyl positivity declines by nearly half in the general U.S. workforce

SECAUCUS, N.J., July 10, 2026 /PRNewswire/ -- Nearly one in five

One in Five American Workers Tested Had a Positive Hair Drug Test in 2025, Signaling Persistent Long-Term Substance Use Patterns

Fri, 10 Jul 2026 09:24:00 -0400

Hair test positivity among American workers reached 19.1% in 2025, potentially reflecting recurring or chronic drug use
15.1% of workers screened for drugs using a hair test were positive for marijuana – up 58.9% from five years ago
Overall workforce urine drug positivity remained above 4% for more than a decade
Healthcare workers scored highest for overall drug positivity, at 5.8%; retail trade had the highest marijuana positivity among worker categories, at 7.6%
Fentanyl positivity declines by nearly half in the general U.S. workforce

SECAUCUS, N.J., July 10, 2026 /PRNewswire/ -- Nearly one in five

Quest Diagnostics integrates cancer tests into Flatiron's OncoEMR platform

Wed, 08 Jul 2026 09:03:18 -0400

Quest Diagnostics (NYSE: DGX) said it is integrating its Haystack MRD ctDNA test and Comprehensive Genomic Profiling services for solid tumor cancers into OncoEMR, an electronic health record system from Flatiron Health, through a pilot program with American Oncology Network (AON) and other community oncology providers.

Quest describes itself as the largest clinical reference lab to integrate oncology tests into OncoEMR using the platform's Molecular Profiling Integration (MPI) ordering feature. Once the full integration is complete, it is intended to give 4,700 clinicians across Flatiron's network of 1,600 community-based cancer care locations in the United States access to Quest's services.

AON, which

Quest Diagnostics Now the Largest Clinical Reference Lab to Extend Oncology Test Access Through OncoEMR MPI

Wed, 08 Jul 2026 08:52:00 -0400